Director of the N.F. Gamaleya Center Alexander Gintsburg in an interview with TASS revealed the timing of the start of trials of a new Russian vaccine against COVID-19 based on virus-like particles.
According to him, clinical trials of the drug are planned to begin in three weeks. “The Ministry of Health understands the relevance of research, all funds have been allocated. We plan to start in three weeks. I hope that by autumn we will already have a certain result,” said the head of the center.
Earlier, Gunzburg spoke about the features of the coronavirus vaccine containing virus-like particles. According to him, the vaccine will be two-component and will not contain a live virus. In addition, the director of the SIC spoke about the date when the vaccine entered civilian circulation. He admitted that this would happen by autumn.
On February 16, it became known that the Gamaleya Center received permission to conduct clinical trials of a vaccine against COVID-19 based on virus-like particles. The first and second phase of clinical trials will be conducted among volunteers 18-55 years old. The vaccine will be tested for tolerability, safety and immunogenicity.
#timing #start #trials #Russian #vaccine #COVID19 #revealed